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Background
In Medellín-Colombia dust mite allergy is prevalent with
high intensity of sensitization. We intended to describe
the tolerability and efficacy of a new vaccine with a new
adjuvant L-tyrosine in this population.
Methods
We realized a 2 years ambispective study for assessment
safety and efficacy of subcutaneous immunotherapy
with a dust mite vaccine with the adjuvant L-tyrosine.
We reviewed the data of 292 patients with allergic rhinitis
and/or asthma. They are sensitized to Dermatophagoides
pteronyssinus or Dermatophagoides farinae and or Blomia
tropicallis. A data base was constructed to allow complete
assessment of the characteristics of the patients. We used
the grading system proposed by the World Allergy Orga-
nization for the classification of the systemic reaction.
Results
Safety
The subjects received a total of 3760 doses and 40 sys-
temic adverse reactions were registered (reaction rate
1.06%). Of this 40 systemic reactions, 34 were in different
patients and 6 patients had 2 reactions each. 28 reactions
were grade 1, 2 and only one reaction was graded 3 and all
were kept under monitoring until complete recovery from
the event. 11 reactions were grade 1 and resolved with
antihistamines alone (1z). No patients died and none
patient was admitted or required ICU or intubation.
Reactions were more common in patients with allergic rhi-
nitis (57%) than in asthmatics (30.8%). 90 % of the reac-
tions occurred with the allergen vaccine with mixture of
D. pteronyssinus plus D. farinae 50%+50 % (16.666 TU/
0.5 ml).
Efficacy
86.3 % of the patients improved markedly their clinical
scores and or medication requirements, the response
were partial for 7.1 % and absent for 6.7 %. The efficacy
was assessment by medical criteria and was grater in
those patients that don’t had systemic adverse reac-
tions in contrast to whom had systemic reactions
(88.9 vs. 66.7%).
Conclusions
Subcutaneous Immunotherapy with L-tyrosine adjuvant
for dust mite allergens is safe and effective in a highly sen-
sitized population in a Latino-American Tropical City.
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